Oxford, UK, 1 August 2020 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Mr Nick Dixon-Clegg to its Board of Directors, representing key investor, Oxford Sciences Innovation. Nick is a Principal at OSI and brings 10 years of experience across investing and corporate finance. Prior to joining OSI Nick was a Principal at Valiance, a MedTech-focused venture capital firm. He was previously an investor at Nordic Capital, a large cap buyout private equity firm, where he focused on Healthcare investing. Prior to that he was an investment banker at Bank of America Merrill Lynch, working as part of the Healthcare coverage team in London. He holds a Triple First Class MA (Cantab) in Natural Sciences from the University of Cambridge.
Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:
“Argonaut Therapeutics has an extensive collection of proprietary assets and the appointment of Nick Dixon-Clegg to its Board continues to demonstrate the importance of Argonaut Therapeutics within the OSI portfolio and its dedicated support for the innovative science being delivered. We are delighted to welcome Nick to the Board and welcome his support as we continue to move towards the clinic.”
About Argonaut Therapeutics
Argonaut Therapeutics is a biopharmaceutical company developing new epigenetic therapies for treating cancer. Its lead programme is focussed on protein arginine methyltransferase 5 (PRMT5) which plays a key role in attaining the malignant phenotype in many different cancers. Argonaut’s deep scientific understanding of cancer-relevant pathways affected by arginine methylation enables a precision medicine approach to treating patients with responsive disease.
Argonaut Therapeutics is a spin-out of Oxford University and maintains a close relationship with the Division of Medical Sciences.